Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses S Elisaf

Showing results (181-190 of 198) with videos related to

Pageof 20
Sort By:
Journal of Diabetes and Its Complications|October 31, 2007
Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: theoretical analysisAntonios H Tzamaloukas, Todd S Ing, Kostas C Siamopoulos, et al.
Lipids|October 29, 2008
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndromeK G Lagos, T D Filippatos, V Tsimihodimos, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|January 22, 2008
Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndromeHaralampos J Milionis, Michael S Kostapanos, Konstantinos Vakalis, et al.
Stroke|February 2, 2008
Metabolic syndrome and its components as predictors of ischemic stroke in type 2 diabetic patientsIoannis Protopsaltis, Panagiotis Korantzopoulos, Haralampos J Milionis, et al.
Expert Opinion on Pharmacotherapy|July 1, 2011
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemiaAris P Agouridis, Vasilis Tsimihodimos, Theodosios D Filippatos, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|October 24, 2006
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrateDimitrios S Christidis, Evangelos N Liberopoulos, Anna I Kakafika, et al.
Current Medical Research and Opinion|July 19, 2006
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)Haralampos J Milionis, Evangelos Rizos, Michael Kostapanos, et al.
International Journal of Cardiology|May 17, 2016
A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE studyDimitrios Alexopoulos, Maria Anastasiou-Nana, Moses S Elisaf, et al.
Angiology|October 19, 2011
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysisVassilios G Athyros, Moses S Elisaf, Theodore Alexandrides, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|November 30, 2019
PCSK9 inhibitors in clinical practice: Novel directions and new experiencesLoukianos S Rallidis, Ioannis Skoumas, Evangelos N Liberopoulos, et al.
Pageof 20

Showing results (181-190 of 198) with videos related to

Sort By:
Pageof 20
Journal of Diabetes and Its Complications|October 31, 2007
Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: theoretical analysisAntonios H Tzamaloukas, Todd S Ing, Kostas C Siamopoulos, et al.
Lipids|October 29, 2008
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndromeK G Lagos, T D Filippatos, V Tsimihodimos, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|January 22, 2008
Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndromeHaralampos J Milionis, Michael S Kostapanos, Konstantinos Vakalis, et al.
Stroke|February 2, 2008
Metabolic syndrome and its components as predictors of ischemic stroke in type 2 diabetic patientsIoannis Protopsaltis, Panagiotis Korantzopoulos, Haralampos J Milionis, et al.
Expert Opinion on Pharmacotherapy|July 1, 2011
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemiaAris P Agouridis, Vasilis Tsimihodimos, Theodosios D Filippatos, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|October 24, 2006
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrateDimitrios S Christidis, Evangelos N Liberopoulos, Anna I Kakafika, et al.
Current Medical Research and Opinion|July 19, 2006
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)Haralampos J Milionis, Evangelos Rizos, Michael Kostapanos, et al.
International Journal of Cardiology|May 17, 2016
A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE studyDimitrios Alexopoulos, Maria Anastasiou-Nana, Moses S Elisaf, et al.
Angiology|October 19, 2011
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysisVassilios G Athyros, Moses S Elisaf, Theodore Alexandrides, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|November 30, 2019
PCSK9 inhibitors in clinical practice: Novel directions and new experiencesLoukianos S Rallidis, Ioannis Skoumas, Evangelos N Liberopoulos, et al.
Pageof 20